Targeting the TGR5-GLP-1 pathway to combat type 2 diabetes and non-alcoholic fatty liver disease.
Incretin-based therapies have shown promise in the treatment of type 2 diabetes. Here we review our current understanding of TGR5 as a target to induce glucagon-like peptide-1 (GLP-1) secretion. These new observations suggest that TGR5 agonists may constitute a novel approach to treat type 2 diabetes, as well as complications of diabetes, such as non-alcoholic fatty liver disease.
Pols
T W H
TW
Laboratory of Integrative and Systems Physiology (LISP), Ecole Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland.
Auwerx
J
J
Schoonjans
K
K
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000494:pharmacology; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives / Q000378:metabolism; D005947:Glucose / Q000378:metabolism; D006801:Humans; D043562:Receptors, G-Protein-Coupled / Q000819:agonists* / Q000502:physiology
D054873:Dipeptidyl-Peptidase IV Inhibitors; D043562:Receptors, G-Protein-Coupled; D052216:Glucagon-Like Peptide 1; D005947:Glucose